Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C26H29N9O3.2ClH |
| Molecular Weight | 588.489 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.Cl.NCCCC[C@H](N)C(=O)NC1=CC=C(C=C1)C(=O)CN2C3=CC=CC=C3N=C2C4=NON=C4NCCC#N
InChI
InChIKey=AOKATNWVGVIXOQ-TXEPZDRESA-N
InChI=1S/C26H29N9O3.2ClH/c27-13-4-3-6-19(29)26(37)31-18-11-9-17(10-12-18)22(36)16-35-21-8-2-1-7-20(21)32-25(35)23-24(34-38-33-23)30-15-5-14-28;;/h1-2,7-12,19H,3-6,13,15-16,27,29H2,(H,30,34)(H,31,37);2*1H/t19-;;/m0../s1
| Molecular Formula | C26H29N9O3 |
| Molecular Weight | 515.567 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Lisavanbulin, also known as BAL-101553, a prodrug of the molecule BAL-27862 with potential antitumor activity. BAL-27862 binds to tubulin, prevents tubulin polymerization, destabilizes microtubules, arrests tumor cell proliferation, and induces cell death in cancer cells. Lisavanbulin participated in phase II clinical trials for the treatment of advanced solid tumors. Besides, the drug participates in a 1/2a clinical study in patients with recurrent glioblastoma and in patients with platinum-resistant or refractory ovarian cancer. In this study, will be characterized the safety and tolerability and to obtain efficacy data in these selected cancer types.
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| The novel microtubule-destabilizing drug BAL27862 binds to the colchicine site of tubulin with distinct effects on microtubule organization. | 2014 Apr 17 |
|
| Initial testing (stage 1) of BAL101553, a novel tubulin binding agent, by the pediatric preclinical testing program. | 2015 Jun |
|
| The Novel Tubulin-Binding Checkpoint Activator BAL101553 Inhibits EB1-Dependent Migration and Invasion and Promotes Differentiation of Glioblastoma Stem-like Cells. | 2016 Nov |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 11:28:27 GMT 2023
by
admin
on
Sat Dec 16 11:28:27 GMT 2023
|
| Record UNII |
5BQ16RIM5D
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
45259013
Created by
admin on Sat Dec 16 11:28:27 GMT 2023 , Edited by admin on Sat Dec 16 11:28:27 GMT 2023
|
PRIMARY | |||
|
1387574-54-0
Created by
admin on Sat Dec 16 11:28:27 GMT 2023 , Edited by admin on Sat Dec 16 11:28:27 GMT 2023
|
PRIMARY | |||
|
300000013059
Created by
admin on Sat Dec 16 11:28:27 GMT 2023 , Edited by admin on Sat Dec 16 11:28:27 GMT 2023
|
PRIMARY | |||
|
5BQ16RIM5D
Created by
admin on Sat Dec 16 11:28:27 GMT 2023 , Edited by admin on Sat Dec 16 11:28:27 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |